JLABS
pioneered the equity-free accelerator model — free shared lab space and mentorship without a forced equity stake — but confirmed in March 2026 that it is winding down its New York City site, at least the fourth JLABS location to close within the past year as J&J consolidates its incubator footprint.
- Country
- United States
shared-lab
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Corporate biotech accelerators (JLABS, Bayer CoLaborator) | finance-investment | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.